SKF 82958 hydrobromide

Discontinued Product

SKF 82958 hydrobromide (Cat. No. 5719) has been withdrawn from sale for commercial reasons.
Description: D1 agonist
Chemical Name: 6-Chloro-2,3,4,5-tetrahydro-1-phenyl-3-(2-propen-1-yl)-1H-3-benzazepine-7,8-diol hydrobromide
Purity: ≥98% (HPLC)
Citations (1)
Literature (4)

Biological Activity for SKF 82958 hydrobromide

SKF 82958 hydrobromide is a D1 agonist. Increases renal blood flow in animal models and promotes contralateral rotation in rats with unilateral lesions of the substantia nigra. Also augments GABAB inhibitory post-synaptic potentials (ipsp) in ventral tegmental area in brain slices.

Technical Data for SKF 82958 hydrobromide

M. Wt 410.73
Formula C19H20ClNO2.HBr
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 74115-01-8
PubChem ID 9909521
Smiles OC1=CC(C(C2=CC=CC=C2)CN(CC=C)CC3)=C3C(Cl)=C1O.Br

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for SKF 82958 hydrobromide

References for SKF 82958 hydrobromide

References are publications that support the biological activity of the product.

Pfeiffer et al (1982) DArgic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines. J.Med.Chem. 25 352 PMID: 7069713

Cameron and Williams (1993) DA D1 receptors facilitate transmitter release. Nature 366 344 PMID: 8247128

View Related Products by Target

View Related Products by Product Action

View all D1 and D5 Receptor Agonists

Keywords: SKF 82958 hydrobromide, SKF 82958 hydrobromide supplier, SKF82958, hydrobromide, dopamine, D1, agonists, agonism, and, D5, Receptors, 5719, Tocris Bioscience

1 Citation for SKF 82958 hydrobromide

Citations are publications that use Tocris products. Selected citations for SKF 82958 hydrobromide include:

Verharen et al (2019) Differential contributions of striatal dopamine D1 and D2 receptors to component processes of value-based decision making. Neuropsychopharmacology 44 2195 PMID: 31254972

Reviews for SKF 82958 hydrobromide

There are currently no reviews for this product. Be the first to review SKF 82958 hydrobromide and earn rewards!

Have you used SKF 82958 hydrobromide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.